FAP Microaggregation for Bladder Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder cancer, such as intravesical instillation of Mycobacterium bovis bacillus Calmette-Guerin (BCG), face challenges including high local morbidity, risk of systemic infection, and limited patient tolerance due to toxicity, necessitating the development of high-affinity, non-toxic targeting strategies for bladder tumor cells.
Innovation Solution
A polyvalent complex is developed that micro-aggregates the Fibronectin Attachment Protein (FAP) to enhance its internalization by bladder cancer cells, utilizing multivalent FAP/FBN complexes that bind to fibronectin and are taken up by cells, inhibiting cell proliferation and inducing apoptosis, and can be used to deliver therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravesical instillation of BCG is used to treat bladder tumors, then antitumor activity is achieved through direct targeting and binding to bladder tumor cells, but high local morbidity and risk of systemic infection occur due to toxicity
Solution Approach 1:
The patent extracts the targeting function from the entire BCG organism by isolating and utilizing only the Fibronectin Attachment Protein (FAP) component. This allows the antitumor targeting mechanism to be preserved while eliminating the toxic effects associated with live bacterial instillation.
Solution Approach 2:
The patent introduces FAP as an intermediary molecule that mediates the targeting function between the therapeutic agent and bladder tumor cells. By using FAP-conjugated cytotoxic agents, the direct bacterial-cell interaction is replaced with a controlled protein-mediated delivery system, reducing morbidity while maintaining antitumor efficacy.
2Reliability
If multiple instillations of BCG are administered to increase therapeutic effect, then antitumor activity is enhanced, but toxicity increases and patient tolerance is limited
Solution Approach 1:
The patent employs a disposable, non-replicating FAP-cytotoxic agent conjugate system that delivers its therapeutic effect in a single administration without the need for repeated instillations. This eliminates the cumulative toxicity problem associated with multiple BCG administrations while maintaining effective antitumor activity.
3Ease of operation
If direct instillation of therapeutic drugs is used to treat bladder tumors, then accessibility to tumor lesions is improved, but impact on tumor cells is limited due to constant urine influx and periodic voiding
Solution Approach 1:
The patent extracts the cell-binding capability from complex drug molecules by using FAP as a dedicated targeting vector. This allows the therapeutic agent to be delivered via a specialized carrier that can bind specifically to tumor cells, overcoming the washout effect of urine flow that plagues direct drug instillation.
Solution Approach 2:
The patent introduces FAP as an intermediary carrier that mediates between the cytotoxic agent and the bladder tumor cell surface. This intermediary system provides stable cell-surface binding and facilitates cellular uptake, ensuring reliable therapeutic impact despite the challenging bladder environment with constant urine influx.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enhanced uptake of cytotoxic agents by bladder cancer cells using the FAP-targeted delivery strategy increases antitumor efficacy while reducing side effects on normal tissue, providing a safer and more effective treatment option.
Implementation Method 1
FAP was shown to interact with α5β1 Integrin-bound fibronectin (FBN) and undergo internalization by tumor cells
Implementation Method 2
the internalization of FAP by bladder tumor cells provides a novel and potentially powerful approach for the delivery of therapeutics
Data Source
AI summary
Composition and methods are disclosed for utilizing microaggregation of FAP-containing complexes to promote their fast internalization. This approach allows the uptake of cytotoxic cargo coupled to either FAP-Antibodies or FAP-liposome complexes by tumor bladder cells. Importantly, this approach is efficient even under serum-free conditions such as the ones found in the lumen of the bladder.